11 completed, 4 terminated, 2 active not recruiting, 2 unknown. 11 Phase 2, 6 Phase 3, 2 Not applicable, 2 Phase 1, 1 Phase 4.
Follow HER2 Positive Breast Cancer: new trials by email Literature Review of HER2 Positive Breast Cancer trials Research Report on HER2 Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses, Cohort B will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 6 doses - HER2 Positive Breast Cancer | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 208 | 2025-04-01 | 2025-03-10 |
| The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study pyrotinib - HER2 Positive Breast Cancer, Pyrotinib Treatment | Phase 2 / Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 964 | 2024-04-30 | 2025-05-06 |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib Neratinib, Loperamide, Colesevelam - Early-stage Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Active not recruiting | Spanish Breast Cancer Research Group | 177 | 2022-08-31 | 2025-04-01 |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Tucatinib, Trastuzumab, Pertuzumab - HER2 Positive Breast Cancer | Phase 3 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 654 | 2022-03-07 | 2026-09-29 |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer tucatinib, trastuzumab deruxtecan - HER2 Positive Breast Cancer | Phase 2 | Completed | Seagen, a wholly owned subsidiary of Pfizer | 70 | 2020-12-01 | 2026-03-23 |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. Pyrotinib and Trastuzumab plus Vinorelbine - HER2 Positive Breast Cancer | Not applicable | Unknown | Henan Cancer Hospital | 48 | 2019-06-01 | 2019-05-15 |
| Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. Pyrotinib plus trastuzumab and docetaxel and carboplatin - HER2 Positive Breast Cancer | Phase 2 | Completed | Henan Cancer Hospital | 75 | 2018-11-20 | 2022-12-01 |
| Adapted Physical Activity for Breast Cancer HER2 Positive Patient Home-based Adapted Physical Activity - HER2 Positive Breast Cancer | Not applicable | Terminated | Centre Jean Perrin | 36 | 2018-04-27 | 2023-11-24 |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients HD201, Herceptin, Docetaxel - HER2 Positive Breast Cancer | Phase 3 | Completed | Prestige Biopharma Limited | 503 | 2018-02-19 | 2024-11-06 |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) Denosumab, nab-Paclitaxel, Epirubicin - Breast Cancer Female NOS, Tubular Breast Cancer Stage II | Phase 2 | Completed | GBG Forschungs GmbH | 780 | 2017-02-13 | 2021-02-02 |
| Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) Copanlisib, Trastuzumab - HER2 Positive Breast Cancer | Phase 1 | Completed | Cancer Trials Ireland | 26 | 2016-04-01 | 2026-04-13 |
| A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer tucatinib, capecitabine, trastuzumab - HER2 Positive Breast Cancer | Phase 2 | Completed | Seagen Inc. | 612 | 2016-01-28 | 2023-08-14 |
| Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer Hemay022 - HER2 Positive Breast Cancer | Phase 1 | Completed | Tianjin Hemay Pharmaceutical Co., Ltd | 28 | 2015-10-14 | 2024-03-01 |
| A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging Carvedilol - HER2 Positive Breast Cancer, Cardiovascular Abnormalities | Phase 2 | Unknown | Northwestern University | 134 | 2015-04-01 | 2024-06-03 |
| A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer lapatinib and capecitabine or vinorelbine - HER2 Positive Breast Cancer | Phase 2 | Completed | Sun Yat-sen University | 159 | 2015-01-09 | 2020-07-15 |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel - Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III | Phase 3 | Completed | GBG Forschungs GmbH | 961 | 2014-12-01 | 2017-07-13 |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients MM-302, Gemcitabine, Capecitabine - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 / Phase 3 | Terminated | Merrimack Pharmaceuticals | 113 | 2014-07-01 | 2017-01-06 |
| Cardiac Safety Study in Patients With HER2 + Breast Cancer Trastuzumab, Pertuzumab, Ado Trastuzumab Emtansine - HER2 Positive Breast Cancer, Left Ventricular Function Systolic Dysfunction | Phase 2 | Completed | Medstar Health Research Institute | 31 | 2013-10-01 | 2022-05-10 |
| Pre Operative Trastuzumab in Operable Breast Cancer Trastuzumab, Placebo - Carcinoma Breast Stage I, HER2 Positive Breast Cancer | Phase 3 | Terminated | Dr Rajendra A. Badwe | 1100 | 2013-05-08 | 2026-10-09 |
| Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer Biomarker Analysis - Breast Cancer, HER2 Positive Breast Cancer | Completed | Cancer Trials Ireland | 330 | 2012-10-12 | 2025-07-08 |
Showing 20 of 21. Sign in to see all of them.
Breast Neoplasms (10) · Carcinoma, Ductal, Breast (2) · Inflammatory Breast Neoplasms (2) · Brain Neoplasms (1) · Cardiovascular Abnormalities (1)
Breast Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Adenocarcinoma (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Ductal (2) · Neoplasms by Histologic Type (2) · Neoplasms, Ductal, Lobular, and Medullary (2) · Neoplasms, Glandular and Epithelial (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1)
Trastuzumab (12) · pertuzumab (4) · Capecitabine (3) · Carboplatin (3) · Cyclophosphamide (3) · Epirubicin (3) · Vinorelbine (3) · pyrotinib (3) · tucatinib (3) · Docetaxel (2) · 130-nm albumin-bound paclitaxel (1) · Ado-Trastuzumab Emtansine (1) · Albumin-Bound Paclitaxel (1) · Carvedilol (1) · Colesevelam Hydrochloride (1)
Cancer Trials Ireland (2) · GBG Forschungs GmbH (2) · Henan Cancer Hospital (2) · Seagen, a wholly owned subsidiary of Pfizer (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Jean Perrin (1) · Dr Rajendra A. Badwe (1) · Infinity Pharmaceuticals, Inc. (1) · Medstar Health Research Institute (1) · Merrimack Pharmaceuticals (1) · Northwestern University (1) · Prestige Biopharma Limited (1) · Seagen Inc. (1) · Spanish Breast Cancer Research Group (1) · Sun Yat-sen University (1)
United States (7) · Spain (6) · China (5) · France (5) · Germany (5) · Italy (4) · Austria (3) · Belgium (3) · Canada (3) · Czechia (3) · Australia (2) · Ireland (2) · Poland (2) · Portugal (2) · Switzerland (2)
Andreas Schneeweiss, MD, Prof. (1) · Corinna Palanca-Wessels, MD, PhD (1) · Jens Uwe Blohmer, MD (1) · Jiani Wang, M.D. (1) · Jorge Ramos, DO (1) · Pedro Santabarbara, MD (1) · Rajendra A Badwe, MS (1) · Sandra M Swain, MD (1) · Zhenzhen Liu (1) · Zhong-Yu Yuan, M.D. (1)
PMID 34252375, PMID 11454999, PMID 14734470, PMID 14737100, PMID 15324695, PMID 16148022, PMID 16404430, PMID 16428482, PMID 17440164, PMID 20142587, PMID 21670457, PMID 27259714, PMID 28314836, PMID 29804905, PMID 30528802, PMID 30852761, PMID 31825569, PMID 32163106, PMID 32468955, PMID 33191846, PMID 33328035, PMID 34214937, PMID 34801353, PMID 34966667, PMID 35238873, PMID 35291977, PMID 35588050, PMID 36454580, PMID 36721174, PMID 38979716, PMID 39024777, PMID 39605014, PMID 41369677, PMID 42431148, PMID 4946080
2015 (1), 2019 (1), 2023 (1)